WASHINGTON — The U.S. House passed a landmark health care measure Thursday that proponents say would dramatically reduce the rising cost of prescription drugs and significantly expand access to health care benefits and services.
The sweeping legislation passed largely along party lines, with 230 lawmakers voting for it and 192 against. Only two House Republicans voted for the bill — Reps. Jaime Herrera Beutler of Washington and Brian Fitzpatrick of Pennsylvania. Fitzpatrick could not immediately be reached for comment for this story.
“Philadelphians and people across the country pay too much for insulin and other life-saving prescription medications,” U.S. Rep. Dwight Evans, D-Philadelphia, said in a statement released by his office. “The price of insulin has gone up 197 percent over the past 10 years! House Democrats passed the Elijah Cummings Lower Drug Costs Now Act to do something about that. President Trump hasn’t kept his promise to let Medicare negotiate drug prices, but House Democrats are taking action.”
The average annual cost of prescription drug treatment increased 57.8 percent between 2012 and 2017, while the annual income for Pennsylvanians only increased 10.4 percent during that same time frame, according to an AARP analysis of 2017 data, the most recent year for which such data were available.
As a result, more than two in 10 state residents (22 percent) stopped taking their drugs as prescribed because of the high cost of medication, the AARP’s analysis showed.
U.S. drug prices are especially high in large part because the federal government doesn’t negotiate lower prices with drug companies, experts say — but the bill passed Thursday would enable it to do so.
Under the bill, lower prices would be available to all consumers, not just beneficiaries of Medicare, the government insurance program serving Americans over age 65 and some younger adults with certain disabilities or who have kidney failure.
The bill would also bar drug companies from charging Americans significantly more than they charge consumers in other countries for the same drugs and from raising prices at rates higher than inflation.
And it would cap out-of-pocket spending on prescription drugs at $2,000 and expand Medicare coverage to include vision, hearing and dental benefits. Savings from lower drug costs — which Democrats said would amount to $500 billion over 10 years — would also be invested in biomedical research, efforts to combat the opioid epidemic, home visitation programs for women and children, and health centers targeting underserved people.
Republicans objected to the legislation, calling it — in the words of GOP Rep. George Holding of North Carolina — a “bad deal” for Americans.
He and other Republicans said regulating drug prices would suppress innovation in biomedical research and stall the development of life-saving drugs and treatments.
“It’s simply a chance we cannot afford to take,” said GOP Rep. Buddy Carter of Georgia.
U.S. Rep. Mike Doyle, D-18th District, rejected the argument, saying Wednesday that drug prices are going up not because of the cost of research and development, but because “drugmakers are jacking up prices wherever and whenever they can maximize their profits.”
Republicans also said the bill would reduce the number of drugs and treatments available on the U.S. market and force Americans to wait longer to access them.
As an alternative, they offered a smaller-scale proposal that would not “impose price controls” but would lower out-of-pocket spending and increase transparency while protecting access to new medicines and encouraging competition.
“Even the [U.S Congressional Budget Office] says [the bill] will kill at least 15 life-saving drugs over the next 10 years. This bill will put America’s elderly and most vulnerable at risk,” U.S. Rep. Guy Reschenthaler, R-14th District, wrote on Twitter. The GOP alternative will “will protect access to new medicines and cures and lower out-of-pocket spending,” he added.
Even the @USCBO says #HR3 will kill at least 15 life-saving drugs over the next 10 years. This bill will put America’s elderly and most vulnerable at risk. #HR19 will protect access to new medicines and cures and lower out-of-pocket spending.
— Rep. Guy Reschenthaler (@GReschenthaler) December 12, 2019
Most Americans think prescription drugs are too expensive, polls show, and one in four insured adults has difficulty paying for them. Majorities favor efforts to reduce their cost — including allowing the federal government to negotiate prices with drug companies.
The Democratic-led bill that passed the House Thursday is not expected to clear the GOP-controlled Senate, and President Donald Trump has threatened to veto it.
The White House said it would “likely undermine access to lifesaving drugs” and cited a report by the Council of Economic Advisers, an executive branch agency, that found that it could lead to the loss or significant delay in the development of as many as 100 new medicines.
But Democrats accused Trump — who pledged in 2016 to “negotiate like crazy” for lower drug prices — of backpedaling on his campaign promise.
“Trump promised in 2016 he would work to lower drug prices,” House Majority Leader Steny Hoyer, D-Md., said on the floor Thursday. “For that reason, he ought to support it.”